-
公开(公告)号：US20130028893A1
公开(公告)日：2013-01-31
申请号：US13199127
申请日：2011-08-19
IPC分类号： A61K39/395
CPC分类号： C07K16/2893 , A61K2039/505 , C07K16/00 , C07K2317/24 , C07K2317/56
摘要： A therapeutic protein, such as a therapeutic antibody, that is modified with a compound that inhibits binding of the protein to its therapeutic target, thereby reducing side effects caused by the protein.
摘要翻译： 治疗性蛋白质，例如治疗性抗体，其被抑制蛋白质与其治疗靶标结合的化合物修饰，从而减少由蛋白质引起的副作用。
-
公开(公告)号：US20170137529A1
公开(公告)日：2017-05-18
申请号：US14974042
申请日：2015-12-18
申请人： Herman Waldmann , Mark Raymond Frewin , Lisa Kim Gilliland , Luis Richardo Simoes Da Silva Graca
发明人： Herman Waldmann , Mark Raymond Frewin , Lisa Kim Gilliland , Luis Richardo Simoes Da Silva Graca
IPC分类号： C07K16/28 , C07K14/705
CPC分类号： C07K16/2893 , A61K47/6849 , A61K2039/505 , C07K14/70592 , C07K16/28 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2318/10 , C07K2319/00
摘要： A pharmaceutical comprising a therapeutic protein that binds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.
-
公开(公告)号：US20100015166A1
公开(公告)日：2010-01-21
申请号：US12316621
申请日：2008-12-15
申请人： Herman Waldmann , Mark Raymond Frewin , Lisa Kim Gilliland , Luis Richardo Simoes da Silva Graca
发明人： Herman Waldmann , Mark Raymond Frewin , Lisa Kim Gilliland , Luis Richardo Simoes da Silva Graca
IPC分类号： A61K39/395 , C07K2/00 , C07K16/00 , C07K19/00 , A61K38/02
CPC分类号： C07K16/2893 , A61K47/6849 , A61K2039/505 , C07K14/70592 , C07K16/28 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2318/10 , C07K2319/00
摘要： A pharmaceutical comprising a therapeutic protein that hinds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.
摘要翻译： 一种药物，其包含与治疗靶标相对的治疗性蛋白质，所述蛋白质用抑制蛋白质与治疗靶标结合的化合物修饰，所述修饰蛋白质有效降低针对所述蛋白质的免疫应答并产生治疗效果 通过结合治疗靶标。 治疗性蛋白质可以是包含结合治疗靶标的抗体结合位点的抗体。
-
公开(公告)号：US20140212418A1
公开(公告)日：2014-07-31
申请号：US13955785
申请日：2013-07-31
申请人： Herman Waldmann , Mark Raymond Frewin , Lisa Kim Gilliland , Luis Richardo Simoes Da Silva Graca
发明人： Herman Waldmann , Mark Raymond Frewin , Lisa Kim Gilliland , Luis Richardo Simoes Da Silva Graca
IPC分类号： C07K16/28
CPC分类号： C07K16/2893 , A61K47/6849 , A61K2039/505 , C07K14/70592 , C07K16/28 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2318/10 , C07K2319/00
摘要： A pharmaceutical comprising a therapeutic protein that hinds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.
摘要翻译： 一种药物，其包含与治疗靶标相对的治疗性蛋白质，所述蛋白质用抑制蛋白质与治疗靶标结合的化合物修饰，所述修饰蛋白质有效降低针对所述蛋白质的免疫应答并产生治疗效果 通过结合治疗靶标。 治疗性蛋白质可以是包含结合治疗靶标的抗体结合位点的抗体。
-
公开(公告)号：US07465790B2
公开(公告)日：2008-12-16
申请号：US09979948
申请日：2001-10-09
申请人： Herman Waldmann , Mark Raymond Frewin , Lisa Kim Gilliland , Luis Richardo Simoes da Silva Graca
发明人： Herman Waldmann , Mark Raymond Frewin , Lisa Kim Gilliland , Luis Richardo Simoes da Silva Graca
IPC分类号： C60K14/00 , A61K39/395
CPC分类号： C07K16/2893 , A61K47/6849 , A61K2039/505 , C07K2317/24 , C07K2317/41 , C07K2317/56 , C07K2318/10 , C07K2319/00
摘要： A pharmaceutical comprising a therapeutic protein that binds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.
摘要翻译： 一种药物，其包含与治疗靶标结合的治疗性蛋白质，所述蛋白质被抑制蛋白质与治疗靶标结合的化合物修饰，所述修饰蛋白质有效降低针对所述蛋白质的免疫应答并产生治疗效果 通过结合治疗靶标。 治疗性蛋白质可以是包含结合治疗靶标的抗体结合位点的抗体。
-
公开(公告)号：US20110014696A1
公开(公告)日：2011-01-20
申请号：US12841064
申请日：2010-07-21
CPC分类号： C12N5/0639 , A61K2039/5154 , A61K2039/5156 , C12N5/0603 , C12N5/064 , C12N2501/052 , C12N2501/22 , C12N2501/23 , C12N2503/02 , C12N2506/02 , C12N2510/00
摘要： Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.
摘要翻译： 公开了胚胎干细胞衍生的树突状细胞，能够成熟的遗传修饰的未成熟树突状细胞，以及用于产生这种细胞的方法。 在一个实施方案中，制备的细胞通过包括以下步骤的方法产生：提供一群胚胎干细胞; 在细胞因子或细胞因子的组合存在下培养胚胎干细胞，其导致胚胎干细胞分化成树突状细胞; 并从培养物中回收树突状细胞。 在另一个实施方案中，细胞可以被遗传修饰。
-
公开(公告)号：US20050037004A1
公开(公告)日：2005-02-17
申请号：US10491112
申请日：2002-09-26
申请人： John Isaacs , Herman Waldmann , Geoffrey Hale
发明人： John Isaacs , Herman Waldmann , Geoffrey Hale
IPC分类号： A61K39/395 , A61P19/02 , A61P29/00 , A61P37/06 , C07K16/28
CPC分类号： C07K16/2809 , A61K2039/505 , C07K2317/41
摘要： Use of an aglycosylated antibody having a binding affinity for the CD3 antigen complex is provided for the manufacture of a medicament for treatment of chronic joint inflammation, and more particularly for treating Rheumatoid Arthritis.
摘要翻译： 提供了对CD3抗原复合物具有结合亲和力的糖基化抗体的用途，用于制备用于治疗慢性关节炎症的药物，更特别是用于治疗类风湿性关节炎。
-
公开(公告)号：US07781213B2
公开(公告)日：2010-08-24
申请号：US12326831
申请日：2008-12-02
CPC分类号： C12N5/0639 , A61K2039/5154 , A61K2039/5156 , C12N5/0603 , C12N5/064 , C12N2501/052 , C12N2501/22 , C12N2501/23 , C12N2503/02 , C12N2506/02 , C12N2510/00
摘要： Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.
摘要翻译： 公开了胚胎干细胞衍生的树突状细胞，能够成熟的遗传修饰的未成熟树突状细胞，以及用于产生这种细胞的方法。 在一个实施方案中，所制备的细胞通过包括以下步骤的方法产生：提供一群胚胎干细胞; 在细胞因子或细胞因子的组合存在下培养胚胎干细胞，其导致胚胎干细胞分化成树突状细胞; 并从培养物中回收树突状细胞。 在另一个实施方案中，细胞可以被遗传修饰。
-
公开(公告)号：US07473556B2
公开(公告)日：2009-01-06
申请号：US11789669
申请日：2007-04-24
CPC分类号： C12N5/0639 , A61K2039/5154 , A61K2039/5156 , C12N5/0603 , C12N5/064 , C12N2501/052 , C12N2501/22 , C12N2501/23 , C12N2503/02 , C12N2506/02 , C12N2510/00
摘要： Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.
-
公开(公告)号：US20060018898A1
公开(公告)日：2006-01-26
申请号：US11180631
申请日：2005-07-14
申请人： Herman Waldmann , Lisa Gilliland , Masahide Tone , Mark Frewin , Louise Walsh
发明人： Herman Waldmann , Lisa Gilliland , Masahide Tone , Mark Frewin , Louise Walsh
IPC分类号： A61K39/395
CPC分类号： C07K16/465 , A61K38/00 , C07K16/2893 , C07K2317/24 , C07K2319/00
摘要： This invention relates to an antibody which is modified version of a therapeutic antibody with affinity for a cell-surface antigen, the antibody having reduced affinity for the antigen compared with the therapeutic antibody as a result of a modification or modifications to the antibody molecule, wherein the antibody is capable of inducing immunological tolerance to the therapeutic antibody. The invention further relates to a method of inducing immunological tolerance to a therapeutic antibody, comprising administering to a patient an antibody which is a modified version of the therapeutic antibody and which has reduced affinity for the antigen as compared with the therapeutic antibody.
-
-
-
-
-
-
-
-
-
搜索结果
44 条记录 (耗时 0.031 秒)
